Pace-termination and pacing for prevention of atrial tachyarrhythmias: results from a multicenter study with an implantable device for atrial therapy

INTRODUCTION

Patients with bradycardia requiring permanent pacing frequently suffer from additional atrial tachyarrhythmias (ATs). This study evaluated the safety and efficacy of atrial antitachycardia pacing (ATP) and the performance of pacing for AT prevention implemented into a new pacemaker.

METHODS AND RESULTS

In patients with conventional indications for permanent pacing, an investigational DDDRP pacemaker (Medtronic AT500, model 7253) was implanted. The primary study objectives were to determine the safety of overall device functioning and its efficacy in terminating spontaneous AT. A secondary endpoint was to determine the reliability of AT detection. Pacemaker memory functions were used to analyze the impact of dedicated pacing algorithms on AT prevention. In 33 European and Canadian centers, 325 patients were enrolled (mean follow-up 2.3+/-1.3 months). Complication-free survival at 3 months was 88%. In 2,145 episodes stored with atrial electrograms, AT detection was confirmed in 97%. The algorithm for continuous overdrive pacing increased the percentage of atrial pacing to 97%. After ATP activation, 16,683 of 52,468 AT episodes were treated (120 patients). Of these, 8,903 episodes (53%) were terminated successfully by ATP. No proarrhythmic effect of preventive pacing or atrial ATP was observed. Preventive pacing algorithms increased the median percentage of atrial pacing from 62% to 97%. However, the number of AT/AF (atrial fibrillation) episodes (4.1 vs 4.1 per patient per day) and the time in AT/AF (13.7% vs 12.8%) was not significantly different before and after activation of preventive pacing.

CONCLUSION

DDDRP pacing with a new system for AT therapy was safe and associated with successful pace-termination of AT in 53% of episodes. Preventive pacing and atrial ATP algorithms represent two new functions that can be implemented safely into pacemaker systems for nonpharmacologic treatment of ATs in patients requiring pacemaker therapy.

Thin co-radial bipolar leads: technology and clinical performance

While bipolar leads offer advantages such as better sensing performance than unipolar leads, their use has been limited by a larger lead diameter and reports about a high failure rate of several bipolar lead models. This has led to the development of thin bipolar leads using a special technology which aims at improving lead safety. Leads with monofilar thin conductors (drawn filled tube) which are individually coated with a very resistant material (ETFE) have been developed. Using a co-radial instead of co-axial bipolar conductor design, the lead diameter could be reduced to 4.5 F compared to 6-7 F of conventional bipolar leads. Bench testing demonstrated a significant improvement of this lead technology with respect to degradation of insulation material by biochemically reactive solutions. Also mechanical characteristics such as resistance to tearing forces and compression showed a high lead durability. From our own experience, co-radial bipolar leads show a favorable electrical performance with the exception of a relatively low pacing impedance. Also during long-term follow-up, the rate of lead failure was very low. These findings are corroborated by other clinical studies which also demonstrated good handling characteristics of thin bipolar leads during implantation.

Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device

OBJECTIVES

This study prospectively analyzed atrial tachyarrhythmia (AT) organization and antitachycardia pacing (ATP) success in patients with an implanted device for AT therapy.

BACKGROUND

In patients with atrial fibrillation (AF), the incidence of regular, slow ATs amendable by ATP is unknown.

METHODS

Forty patients with previously documented AT (70% with AF) received a new pacemaker with atrial electrogram (AEG) storage and atrial ATP capabilities for standard pacing indications. The AEGs acquired during the first month (study phase 1) were classified into high (type I), intermediate (type II) and low (type III) degrees of organization. Atrial ATP was then activated, and treated AT episodes were retrieved three and six months after implantation (study phase 2).

RESULTS

Of 824 AEGs retrieved before ATP activation (study phase 1), 351 (43%) were classified as type 1, 47% as type II and 10% as type III. Episodes of AT starting as type I (35%) and type II or III (65%) maintained their type over 1 min in 73%. All patients with an exclusive history of AF also showed type I AEGs. In 361 subsequently treated AT episodes (study phase 2), ATP was successful in 62% of type I and 34% of type II episodes, but not in type III (p < 0.0001).

CONCLUSIONS

The majority of patients with a history of AF show not only disorganized but also highly organized AT episodes, which can be successfully terminated by ATP.

[P-wave signal averaging-ECG: normal values and reproducibility]

Signal averaging techniques are used for detection of low amplitude, high frequency signals in the surface ECG. P-wave signal-averaging has been used to predict the risk for development of atrial tachyarrhythmias in patients with structural heart disease. There is, however, a lack of prospective studies evaluating normal values of the P-wave signal-averaged ECG in healthy individuals. Moreover, day-to-day reproducibility of results of P-wave signal-averaging is not precisely known. Thus, the aim of this study was to determine normal values and reproducibility of time-domain P-wave signal-averaging in a large cohort of healthy volunteers. A commercially available device (MAC 5000, Marquette Hellige) was used for signal-averaging. A vector magnitude was calculated from Frank's orthogonal leads after P-waves were sampled and filtered with a spectral filter using fast fourier transform. We examined 123 volunteers without cardiovascular disease at two occasions. Mean P-wave duration was 114 +/- 13 ms for the overall study population. There was a slight but statistically significant increase in filtered P-wave duration with age (r = 0.32, p < 0.001). All values were reliably reproducible upon the second examination (r = 0.624 to 0.706, p < 0.0001). These results may serve as a future reference to other studies examining patients with structural heart disease.

[Mode-switching algorithms: programming and usefulness]

BACKGROUND

Automatic mode switching is defined as the ability of a pacemaker to reprogram itself from tracking to non-tracking mode in response to atrial tachyarrhythmias, and to regain tracking mode as soon as the tachyarrhythmia terminates. In contrast to upper rate behavior, mode switching does not only limit atrial tracking at a certain rate but actively drives the ventricular pacing rate back to lower rate or sensor rate as long as the atrial tachyarrhythmia persists. In contrast to DDD with mode switch, AV synchrony may be lost in DDIR mode if the sinus rate exceeds the sensor rate. DDD pacing with mode switching represents a valuable option in patients with AV block and paroxysmal atrial tachyarrhythmias. It may prevent the transition from paroxysmal to permanent atrial fibrillation after AV node ablation to a higher extent than VVI(R) pacing. On the other hand, patients with sinus node disease and normal AV conduction may benefit from DDIR mode with long AV interval. Mode switching should provide a rapid, sensitive and specific detection of atrial tachyarrhythmias, fast switch to non-tracking mode without ventricular pacing at the upper rate limit, adequate ventricular rate during the atrial tachyarrhythmia, rapid, sensitive and specific detection of conversion to sinus rhythm and fast switch back to tracking mode. In addition, oscillations between DDD and DDI mode with sudden ventricular rate changes should be avoided. MODE-SWITCHING ALGORITHMS: To achieve these aims, different mode-switching algorithms have been developed which all show specific disadvantages: reliable but slow response to atrial tachyarrhythmias, fast but unspecific switch to non-tracking mode, mode oscillations, inclination to inadequate mode-switching due to ventricular far-field sensing, failure to perform modeswitching during atrial flutter or intermittent atrial undersensing. Some of these problems can be avoided by careful atrial lead implantation providing atrial signals above 2 mV and avoiding ventricular far-field signals. Programming of mode-switching related parameters (e.g. atrial rate and number of fast beats required for mode switch), atrial blanking times, and atrial sensitivity can solve some of the problems with mode switching. Clinical results show a strong influence of device programming and atrial undersensing on mode-switching performance. Some data suggest a superiority of fast mode-switching algorithms with regard to clinical symptoms. However, loss of AV synchrony during sinus rhythm due to premature or inadequate mode switching may limit the benefit of fast mode switching.

FURTHER DEVELOPMENTS

Improved performance may be achieved by a combination of different mode-switching algorithms (e.g. one algorithm for detection of atrial fibrillation, another one for detection of atrial flutter). In addition, programmability of several algorithms (e.g. mean atrial rate, beat-to-beat, x out of y) within the same device and atrial cycle-dependent sensitivity adjustment similar to automatic gain control in implantable defibrillators may further increase the clinical use of automatic mode switching.

Discrimination between ventricular and supraventricular tachycardia by dual chamber cardioverter defibrillators: importance of the atrial sensing function

Although the addition of atrial sensing in dual chamber ICDs may improve the ability of the device to discriminate between supraventricular (SVT) and ventricular tachycardia (VT), atrial sensing errors may also negatively affect tachycardia classification. This prospective study evaluated the incidence of atrial sensing errors in a dual chamber ICD and their impact on VT/SVT discrimination. In 145 patients, a dual chamber ICD (Defender) was implanted. Analysis of 1,241 tachycardia episodes stored during a mean follow-up of 14+/-8 months revealed atrial sensing errors in 817 (66%) episodes. Upon expert review, device-based classification was confirmed in 509 (98%) of 522 SVT episodes. No false device-based SVT classification was related to atrial sensing errors. Of 719 episodes classified as VT by the device, 645 (90%) were confirmed. There were 74 episodes of false-positive VT detection. Of these, 63 were related to atrial sensing errors: atrial undersensing in 58 (92%) and atrial oversensing in 5 (8%) episodes. Atrial sensing errors led to incorrect VT/SVT discrimination in 51 (4%) of 1,241 episodes. Only the occurrence of paroxysmal atrial fibrillation and abdominal site of device implantation showed a significant influence on false VT/SVT discrimination. Atrial sensing errors are frequently encountered in dual chamber ICDs. Due to the VT/SVT discrimination algorithm, atrial sensing errors only led to misclassification in 4 % of all episodes, mainly due to atrial undersensing. No VT underdetection due to atrial oversensing occurred.

Current status of dual-sensor pacemaker systems for correction of chronotropic incompetence

Rate-adaptive pacing has been shown to improve exercise capacity in patients with chronotropic incompetence. However, all sensors used to adapt the pacing rate to meet metabolic demands show typical limitations. To overcome these, concepts using 2 sensors for rate adaptation have been developed, combining an unspecific but fast-reacting sensor with a specific but slower-reacting one. Clinical performance of these dual-sensor pacemaker systems is related to 3 factors: (1) choice of sensors, (2) mode of sensor integration, and (3) algorithms for automatic optimization of the integrated sensor response. Clinical studies using dual-sensor rate-adaptive pacing systems have demonstrated their ability to mimic normal sinus rate during different forms of exercise, avoiding inadequate or delayed rate response. However, to avoid combining the disadvantages of both single sensors, dual-sensor rate-adaptive systems need effective automatic algorithms. Sensor cross-check should be quick and combine fast reactivity and high specificity, particularly so as to prevent overpacing. Programmable rate response-related parameters should continuously be optimized. The pacemaker should provide diagnostic facilities during exercise to simulate short-term sensor performance at different settings and memory functions to evaluate long-term sensor performance. Assessment and eventually deactivation of all automatic functions should be possible. Finally, even with automatic algorithms for sensor optimization, maximal benefit from a dual-sensor system can only be achieved if the physician is able to identify and correct pitfalls of each system.

Diagnostic value of stored electrograms in single-lead VDD systems

Evaluation of the quality of atrial sensing is indispensable to monitor the performance of VDD single-lead systems. In addition to counters, a new VDD system offers storage of intracardiac electrograms (EGMs). The clinical contribution of stored EGMs in a VDD pacemaker was prospectively examined in a multicenter study, and the reliability of its counters was evaluated on the basis of EGM information.

METHODS

A VDD system (Pulsar 870, Guidant Co.) was implanted in 46 patients with atrioventricular block. EGM storage was activated upon detection of ventricular tachycardia (VT), recurrent premature ventricular complexes (PVCs), and mode switch ("atrial tachy reaction," ATR). Stored EGMs were retrieved before discharge of the patients from the hospital, and at 6-week, 3-month, and 6-month follow-up.

RESULTS

A total of 440 stored EGMs were retrieved and analyzed. Of 30 VT episodes detected, 2 (7%) were confirmed, and all others were attributable to ventricular oversensing. One postmortem interrogation documented VT as the cause of sudden death. Of 175 EGMs stored upon detection of PVCs, 43 episodes (25%) were confirmed and 124 (70%) showed intermittent atrial undersensing with spontaneous AV conduction; in 8 episodes (5%) no abnormality was observed. Of 235 episodes stored upon ATR, 82 (35%) were confirmed and 153 were due to atrial oversensing.

CONCLUSIONS

(1). Stored EGMs indicated a high percentage (69%) of event misdiagnosis by the pacemaker. Thus, pacemaker counter information without the availability of stored EGMs should be interpreted with caution. (2). Misclassified events are of high clinical importance since they unmask otherwise unsuspected intermittent under- or oversensing.

Atrial pacing in the prevention of paroxysmal atrial fibrillation: first results of a new combined algorithm

Pacing algorithms for prevention of atrial tachyarrhythmia (AT) are under clinical evaluation. The present study prospectively evaluated the efficacy of three simultaneously active algorithms for AT prevention and aimed at identifying patients in whom atrial preventive pacing (APP) may be particularly successful.

METHODS

In 31 patients with conventional pacing indications and paroxysmal AT, a DDDRP pacing system was implanted, which stores 35 AT episodes with atrial electrograms and marker annotations. Counters and stored AT episodes were retrieved 30 days after implant. APP algorithms (atrial preference pacing, atrial rate stabilization, postmode switching overdrive) were activated. Counters and stored AT episodes were again retrieved 60 days later. The number and duration of AT episodes was measured. Several clinical variables were examined with respect to their ability to identify candidates for APP.

RESULTS

During APP, the mean number of AT episodes/patient/day decreased from 7.67 to 1.68 (P = 0.04). However, time in AT was not significantly reduced (9.45% versus 10.41%). APP decreased the number of episodes/day in 11 patients and increased it in 9 patients. No clinical parameters predicting APP success was identified.

CONCLUSIONS

APP using three algorithms significantly reduced the mean number of AT episodes/patient/day. However, the time during which patients were in AT was not reduced. No clinical variable predicted the success or failure of APP.

Influence of the pacing rate on the atrioventricular conduction time during aerobic and anaerobic exercise: basic concepts for a dromotropically controlled rate responsive pacemaker

The dromotropic pacemaker concept needs a rate responsive algorithm in which the pacing rate is controlled by the atrioventricular conduction time (AVCT). To develop basic concepts for such a rate responsive algorithm, the influence of the pacing rate on the AVCT was investigated. Seven patients (62 +/- 7.8 years) with sick sinus syndrome and intact atrioventricular conduction underwent two cardiopulmonary exercise tests (CPX) on a treadmill. According to the determination of the anaerobic threshold (AT) and the patients maximum capacity in the first incremental CPX the work rate for two exercise levels below and above the AT were chosen for the second constant workload CPX. The calculation of the optimal pacing rate (HRopt) was based on the oxygen uptake (VO2) during exercise after reaching steady-state conditions. According to the increase of the VO2 from 14.8 +/- 2.3 mL/min per kilogram during aerobic work (38.3 +/- 16.0 W) to 19.4 +/- 4.7 mL/min per kilogram during anaerobic work (80.6 +/- 32.3 W), the HRopt was calculated to be 98.6 +/- 6.9 beats/min and 116.4 +/- 4.7 beats/min. Starting from HRopt, the pacing rate was increased (overpacing) and decreased (underpacing) by about 5 beats/min every minute. At optimal pacing rate the AVCT decreased significantly from 233.0 +/- 30.5 ms during aerobic work and to 226.4 +/- 27.3 ms during anaerobic work (P < 0.05). Whereas overpacing induced a significant prolongation of the AVCT during aerobic work (4.17 +/- 1.78 ms per 10 beats/min) and anaerobic work (3.84 +/- 1.60 ms per 10 beats/min), underpacing yielded a significant shortening of the AVCT by about 4.49 +/- 2.64 ms per 10 beats/min during aerobic work and 4.75 +/- 1.87 ms per 10 beats/min during anaerobic work (P < 0.01). The slopes of the regression lines of the relationship between AVCT and pacing rate were not significantly. different. Based on the reciprocal relationship of heart rate (HR) and AVCT, basic concepts may be established for a dromotropic rate responsive algorithm.

Results from the use of a preshaped lead for single-pass VDD/DDD stimulation

Main criticisms about single-pass VDD stimulation in patients with AV block and normal sinus node function concern atrial undersensing in a lead with floating atrial electrodes, and loss of AV synchrony if sinus node dysfunction develops after implantation. We evaluated the concept of a preshaped single-pass lead designed to place the atrial ring electrodes in a constant position close to, or in contact with, the atrial wall. A preshaped lead (Model 2775, Medtronic Inc.) was implanted in 14 patients and followed for up to 2 years. Mean P wave amplitudes (PWAs) were 3.1 mV at implantation, 1.2 mV at predischarge, and 1.3 mV after 12 months. In all patients, minimal PWAs were well above maximal atrial sensitivity of the pacemaker in all body positions during the complete follow-up; atrial undersensing was not observed. Effective atrial stimulation was possible in all patients at implantation (mean stimulation threshold 2.5 V at 0.50 ms), in 11 patients on the first day after implant (mean stimulation threshold 0.22 ms at 5.0 V), in 10 patients after 1 month (mean stimulation threshold 0.57 ms at 5.0 V), and in 10 patients after 1 year (mean stimulation threshold 0.65 ms at 5.0 V). Intermittent phrenic nerve stimulation could be provoked in six patients. In conclusion, the concept of a preshaped single-pass lead facilitated implantation, improved atrial sensing performance, and allowed atrial stimulation in some patients. Still, further improvements are necessary to decrease the atrial stimulation thresholds to acceptable values in all patients.

Relationship between atrioventricular delay and oxygen consumption in patients with sick sinus syndrome: relevance to rate responsive pacing

To develop a dromotropic-controlled rate adaptive algorithm for patients with sick sinus syndrome (SSS) and intact AV conduction, 14 pace-maker patients with SSS underwent cardiopulmonary exercise testing (CPX). During exercise, the pace-maker was programmed in an AAT mode without rate adaptation, whereby 3 patients developed supraventricular arrhythmia and 11 patients kept sinus rhythm. Chronotropic incompetence (CI) at heart rate (HR) < 95 beats/min at the anaerobic threshold (AT) was found in five patients. In patients with chronotropic competence (CC), the HR increase was significantly greater than in CI patients (rest: 73.2 +/- 12.6 vs. 64.2 +/- 4.0 beats/min;AT:101.2 +/- 6.2 vs. 82.0 +/- 5.1 beats/min;peak: 135.2 +/- 10.7 vs. 103.2 +/- 10.9 beats/min). There was no significant difference in the AVD between CC and CI patients (rest: 167.7 +/- 38.6 vs. 170.8 +/- 22.5 ms, AT: 156.2 +/- 30.7 vs. 163.6 +/- 21.6 ms, peak: 144.7 +/- 29.0 vs. 152.4 +/- 15.0 ms). The correlation coefficient between HR increase and VO2 was +1.0 and between AVD decrease and VO2 - 1.0 in both groups. An increase in pacing rate from 75 beats/min to 120 beats/min without exercise (overpacing) led to a prolongation of the AV interval of about 30.6 +/- 14.2 ms. Based on this closed loop control with negative feedback, a dromotropic rate adaptive algorithm for patients with SSS and intact AV conduction could be developed.